Biogen Shares Slightly Higher

Biogen was just higher after the European Medicines Agency (EMA) said it is provisionally restricting the use of the multiple sclerosis medicine Zinbryta to patients with highly active relapsing disease who failed to respond to certain other treatment, and to patients with rapidly evolving relapsing disease who cannot be treated with other medicines. In addition, patients with liver injury must not be given the medicine.

It said this is a precaution, to ensure Zinbryta continues to be used as safely as possible while a review of its liver safety is ongoing.

Leave A Reply

Your email address will not be published.